Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2023)

Theravance Biopharma has reported Restructuring Costs over the past 3 years, most recently at $1.2 million for Q2 2023.

  • Quarterly Restructuring Costs fell 61.03% to $1.2 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2023, down 93.95% year-over-year, with the annual reading at $2.7 million for FY2023, 78.63% down from the prior year.
  • Restructuring Costs was $1.2 million for Q2 2023 at Theravance Biopharma, down from $1.6 million in the prior quarter.
  • Over five years, Restructuring Costs peaked at $33.0 million in Q3 2022 and troughed at $1.2 million in Q2 2023.
  • The 3-year median for Restructuring Costs is $9.3 million (2022), against an average of $11.7 million.
  • Year-over-year, Restructuring Costs skyrocketed 114.29% in 2022 and then tumbled 83.12% in 2023.
  • A 3-year view of Restructuring Costs shows it stood at $18.4 million in 2021, then surged by 79.63% to $33.0 million in 2022, then crashed by 96.46% to $1.2 million in 2023.
  • Per Business Quant, the three most recent readings for TBPH's Restructuring Costs are $1.2 million (Q2 2023), $1.6 million (Q1 2023), and $33.0 million (Q3 2022).